TechCrunch Industry News BioticsAI gains FDA approval for its AI-powered fetal ultrasound product; plus, Sequoia to invest in Anthropic
Jan 20, 2026
Biotics AI has secured FDA approval for its innovative AI software that detects fetal abnormalities during ultrasounds. The founder's obstetrician family background provides a personal touch to the product's inspiration. Meanwhile, Sequoia Capital is making waves by investing in Anthropic, an AI startup, despite traditional venture capital norms against backing competing firms. The massive funding round aims for a $25 billion raise, with involvement from tech giants like Microsoft and NVIDIA, highlighting Sequoia's longstanding ties with influential figures in the AI space.
AI Snips
Chapters
Transcript
Episode notes
Founder’s Medical Roots Shaped The Product
- Robby Bostami grew up in a family of obstetricians and often traveled with his mother providing maternal care across the U.S.
- He leveraged that upbringing to found Biotics AI and focus on fetal ultrasound quality and clinical impact.
AI Needs Real-World Validation Across Demographics
- Biotics AI pairs computer vision with workflow integration to assess ultrasound quality and automate reporting.
- They emphasized validating performance across diverse demographics to reduce care disparities.
Plan Regulatory And Product Work Together
- Design product, clinical validation, and regulatory pathway together rather than sequentially to move faster.
- Align engineering, product, clinical, and regulatory teams from the start to reduce delays.